Immuneering to Participate in Jefferies 2021 London Healthcare Conference

CAMBRIDGE, Mass., Nov. 10, 2021 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a biopharmaceutical company advancing a robust pipeline of oncology and neuroscience product candidates that are designed to uniquely disrupt cellular signaling dynamics, today announced that Company management will participate in the upcoming Jefferies 2021 London Healthcare Conference, taking place virtually and in-person from November 16-19, 2021 in London, England. At the conference, Ben Zeskind, Ph.D., Co-Founder, President and Chief Executive Officer of Immuneering, Biren Amin, MBA, Chief Financial Officer and Brett Hall, Ph.D., Chief Scientific Officer, will participate virtually to share commentary with investors around the Company’s pipeline, platform and business strategy.

Immuneering will present virtually at the Jefferies London Healthcare Conference as follows:

Date:			Thursday, November 18, 2021
Time:			08:00 Greenwich Mean Time / 03:00 AM Eastern time
Webcast:			https://wsw.com/webcast/jeff201/register.aspx?conf=jeff201&page=imrx&url=https://wsw.com/webcast/jeff201/imrx/1865664

The presentation will be webcast live and available on demand from November 18, 2021 at 3:00 am ET to November 19, 2021 at 12:00 pm ET at the above link.

About Immuneering Corporation                                        
Immuneering is a biopharmaceutical company with an emerging pipeline focused on improving patient outcomes across a spectrum of debilitating oncologic and neurologic diseases by applying its deep knowledge of translational bioinformatics to every stage of the drug development process. Immuneering has more than a decade of experience in translational bioinformatics and generating insights into drug mechanisms of action and patient treatment responses. Building on this experience, Immuneering has developed a disease-agnostic platform that enables the company to utilize human data, novel biology and chemistry, and translational planning to create and advance its wholly owned pipeline. Immuneering’s current development programs in oncology are focused on providing potential treatments for patients with solid tumors caused by mutations of oncologic signaling pathways, including the MAPK pathway. Immuneering’s lead product candidate, IMM-1-104, is designed to be a highly selective dual-MEK inhibitor that further disrupts KSR for the treatment of advanced solid tumors in patients harboring RAS mutant tumors. Additionally, Immuneering has six other oncology programs in the discovery stage that are designed to target either the MAPK or mTOR pathway, and two neuroscience programs in the discovery stage.        

Forward-Looking Statements

This press release includes certain disclosures that contain "forward-looking statements." Forward-looking statements are based on Immuneering’s current expectations and are subject to inherent uncertainties, risks and assumptions that are difficult to predict. Factors that could cause actual results to differ include, but are not limited to, the risks inherent in oncology and neuroscience drug development, including target discovery, target validation, lead compound identification, lead compound optimization, preclinical studies and clinical trials. These and other risks and uncertainties are described more fully in the section titled "Risk Factors" in the final prospectus related to the offering filed with the U.S. Securities and Exchange Commission. Forward-looking statements contained in this announcement are made as of this date, and Immuneering undertakes no duty to update such information except as required under applicable law.        

Corporate Contact:
Rebecca Kusko, Ph.D.
Immuneering Corporation
617-500-8080
rkusko@immuneering.com

Investor Contact:
Anne Marie Fields
Managing Director
Rx Communications
afields@rxir.com